Codexis cuts 25% of staff, slashes drug programs while doubling down on RNAi tech

The enzyme engineering specialists at Codexis are giving up on making their own therapies, instead focusing on selling its technologies and services to customers — including processes to support commercial-scale manufacturing of RNAi drugs.

Stephen Dilly

As a result, the company said it will…
Click here to view original post